Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eli Lilly and CoXSWX:LLY -2.60%92 3-Year FCF Growth Rate is 9.30% as of Jun. 2026, which is at its 10-year median of 9.30. GuruFocus rates XSWX:LLY with a GF Score™ of 92/100 and a GF Value™ of CHF1,244.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 659 Drug Manufacturers companies, Eli Lilly and Co ranks better than 50.23% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Eli Lilly and Co was 116.20% per year. The lowest was -57.40% per year. And the median was 9.30% per year.
Eli Lilly and Co (XSWX:LLY) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Eli Lilly and Co 3-Year FCF Growth Rate Related Terms
XSWX:LLY vs JNJ, ABBV, MRK: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's 3-Year FCF Growth Rate falls into.
Eli Lilly and Co 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Eli Lilly and Co (XSWX:LLY) has a 3-Year FCF Growth Rate of 9.30% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Eli Lilly and Co and its competitors. This is near median its historical median of 9.30. According to the industry distribution chart, Eli Lilly and Co ranks #328 out of 659 companies in the Drug Manufacturers industry, placing it in the top 49.8%.
Is Eli Lilly and Co's 3-Year FCF Growth Rate too high?
Eli Lilly and Co's current 3-Year FCF Growth Rate of 9.30% is near median its 10-year median of 9.30. The Drug Manufacturers industry median 3-Year FCF Growth Rate is 9.00. Eli Lilly and Co's value of 9.30% is 3.3% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #328 out of 659 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's 3-Year FCF Growth Rate compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #328 out of 659 companies for 3-Year FCF Growth Rate. This puts Eli Lilly and Co in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 9.00. Eli Lilly and Co's value of 9.30% is 3.3% above this benchmark. While the company's 10-year median is 9.30 vs. the industry median of 9.00, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 9.00, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current 3-Year FCF Growth Rate of 9.30% is 3.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current 3-Year FCF Growth Rate is 9.30%, which is near median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,244.46, compared to a current price of CHF935.00 — trading 24.9% below its estimated fair value. The current 3-Year FCF Growth Rate is 9.30%, which is near median its 10-year median of 9.30 and 3.3% above the Drug Manufacturers industry median of 9.00. Eli Lilly and Co's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current 3-Year FCF Growth Rate is 9.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF935.00 is trading 24.9% below its estimated GF Value™ of CHF1,244.46.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
3-Year FCF Growth Rate: 9.30% (near median its 10-year median of 9.30)
GF Value™: CHF1,244.46 vs. price of CHF935.00 (24.9% below fair value)
Industry Position: 3.3% above the Drug Manufacturers median (#328 of 659)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
92GF Score
Get the complete analysis for XSWX:LLY
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
